Dateline City:
KENILWORTH, N.J. & SEOUL, South Korea
Data Presented for the First Time at the EULAR Annual Meeting
Phase 1 Data for SB2, SB4 and SB5, an Investigational Biosimilar of Humira (Adalimumab), also Presented
KENILWORTH, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical
studies of SB4, an investigational biosimilar of Enbrel (etanercept),
and SB2, an investigational biosimilar of Remicade (infliximab), met
their primary endpoints, demonstrating equivalence to the originator
medicine in patients with moderate to severe rheumatoid arthritis (RA)
despite methotrexate therapy.
Language:
English
Contact:
Merck Media:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orMerck Investors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879orSamsung Bioepis Media:Jamyung Cha, (82) 32-455-6137orSamsung Bioepis Investors:Sungjoon Park, (82) 32-455-6120
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more